摘要
目的 探讨生物反馈联合药物治疗慢性前列腺炎的临床疗效。方法 将145例慢性前列腺炎患者根据美国国立卫生院（NIH）前列腺炎分型标准分型后，随机分为治疗组和对照组。治疗组（85例）均接受生物反馈治疗20次，每次20min，同时给予常规药物治疗；对照组（60例）仅给予常规药物治疗。以NIH慢性前列腺炎症状评分（NIH-CPSI）和前列腺按摩液（EPS）中自细胞计数为疗效评价指标。结果 治疗组NIH-CPSI总分治疗前后分别为（26．65±6．32）、（10．34±5．07）分，平均降低16．31分，症状程度评分治疗前后分别为（19．76±4．77）、（7．25±3．38）分，平均降低12．51分；对照组NIH—CPSI总分治疗前后分别为（25．57±6．11）、（15．45±5．76）分，平均降低10．12分，症状程度评分治疗前后分别为（18．23±4．65）、（10．56±4．21）分，平均降低7．67分。治疗组NIH—CPSI总分与症状程度评分的下降幅度均比对照组更明显（P〈0．01）。治疗组总有效率90．6％（77／85），总显效率67．1％（57／85），对照组总有效率66．7％（40160），总显效率45．0％（27／60），两组比较差异均有统计学意义（P〈0．05或〈0．01）。结论 生物反馈联合药物治疗慢性细菌性前列腺炎及非细菌性前列腺炎（慢性盆腔疼痛综合征）安全、有效，患者的依从性好。
Objective To study the efficacy of biofeedback combined with drugs in the treatment of chronic prostatitis. Methods A total of 145 patients who had been diagnosed as chronic prostatifis were divided into two groups according to NIH classification system for prostatitis. The control group （n = 60）received the general drugs, while the treatment group （n =85 ） received the treatment of biofeedback therapy in addition to the general drugs. The efficacy was evaluated by the NIH chronic prostatitis symptom index （NIH-CPSI） and the WBC count in EPS after the treatment. Results The overall NIH-CPSI scores were averagely reduced by 16.31 scores in treatment group and 10.12 scores in control group, and the symptom scores were averagely reduced by 12.51 scores in treatment group and 7.67 scores in control group ,there were significant difference in reducing between two groups （P 〈 0.01 ）. The total effective rates were 90.6% in treatment group and 66.7% in control group （P 〈 0.05 ）. Conclusion Biofeedback combined with drugs in the treatment of chronic bacterial prostatitis and nonbactefial prostatitis is effective and safe. The patients have good compliance with the therapy.
出处
《中国医师进修杂志（外科版）》
2007年第8期19-21,共3页
Chinese Journal of Postgraduates of Medicine
